Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
Giandomenico RovielloSebastiano ButiCarlo CattriniAlessia MennittoCarlo MessinaChiara AiroldiGianmarco VanniniMelissa BersanelliPublished in: Therapeutic advances in urology (2021)